Lennox-Gastaut syndrome

Lennox–Gastaut syndrome (LGS) is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life. LGS is characterized by a triad of signs including frequent seizures of multiple types, an abnormal EEG pattern of less than 2.5 Hz slow spike wave activity,

LGS children with a history of perinatal hypoxia or other perinatal event have earlier age of onset of seizures

Links

Endoscopic epilepsy surgery: Emergence of a new procedure

Rufinamide

Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study

Clobazam

ARCHER ET AL.Ictal EEG features and peri-ictal SPECT of tonic seizures in LGS

Clobazam was approved by FDA on 2011 as adjuntive treatment of seisures associated with LGS in patients 2 year and older

Clobazam is equally safe and efficacious for seizures associated with Lennox–Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results

stable dosage of clobazam for LGS are associated Epilepsia 55: 558(2014)

Disease classification WHO

G40.7 Lennox-Gastaut syndrome

ICD-10 online

  Interwiki via Wikidata